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INTRODUCTION 
Hypertrophic cardiomyopathy (HCM) is a complex and relatively common 
genetic cardiac disease that has been the subject of intense scrutiny and investigation 
for more than 40 years.1-3Hypertrophic Cardiomyopathy is an important cause of 
disability and death in patients of all ages, although sudden and unexpected death in 
young people is perhaps the most devastating component of its natural history. 
Because of marked heterogeneity in clinical expression, natural history, and prognosis, 
HCM often represents a dilemma to primary care clinicians and cardiovascular 
specialists, even to those for whom this disease is a focus of their investigative careers. 
Controversy abounds with regard to diagnostic criteria, clinical course, and 
management for which difficult questions often arise, particularly among practitioners 
infrequently engaged in the evaluation of HCM patients. Consequently, it is timely to 
place in perspective and clarify many of these relevant clinical issues and profile the 
rapidly evolving concepts regarding HCM.  
Epidemiological investigations with diverse study designs have shown similar 
estimates for prevalence of phenotypically expressed HCM in the adult general 
population at about 0.2% (1:500).4 Therefore, HCM is not rare and is the most 
common genetic cardiovascular disease, with reports from many countries. 
Nevertheless, a substantial proportion of individuals harboring a mutant gene for HCM 
are probably undetected clinically. Hypertrophic cardiomyopathy is, however, 
uncommon in routine cardiologic practice, affecting no more than 1% of outpatients.5  
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This limited exposure of clinicians to HCM understandably accounts for the 
uncertainty that prevails regarding this disease and its management. 
Recognition of the frequency with which hypertrophic cardiomyopathy (HC) 
occurs in the population is critical to understanding its demographics and public health 
implications. However, few data are available for estimating HC prevalence in large 
populations of different age strata and ethnic or racial groups.. The study population 
was comprised of subjects attending Cardiology Department during the period of Nov 
2006-Oct 2007 to determine the prevalence of HCM in this population based on left 
ventricular (LV) wall thickness >/=15 mm and a nondilated cavity that was not 
associated with another cardiac disease and was sufficient to produce the magnitude of 
hypertrophy evident. 
Indian study regarding HCM was limited regarding clinical manifestation, 
types and risk stratification. Hence this study had been put forth to review  the  
prevalence in this part of the country,  symptom analysis, clinical manifestation, types 
of HCM, and risk stratification for sudden death and also for genetic analysis  
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REVIEW OF LITERATURE 
A systematic search of the medical literature involving articles primarily 
related to English-language HCM publications (1966-2007) from a varied and 
extensive number of authors and centers was reviewed through MEDLINE or 
bibliographies of published articles. Published accounts of HCM have come 
disproportionately from a relatively small group of highly selected centers in the 
United States, Canada, and Europe. Many clinical HCM studies are observational and 
retrospective in design because of difficulty in organizing large prospective and 
randomized clinical trials for a disease with heterogeneous expression, selective 
referral patterns, and diverse mechanisms for morbidity and mortality. Therefore, in 
HCM, the level of evidence governing management decisions is derived primarily 
from nonrandomized studies. 
NOMENCLATURE 
Since the first modern description in 1958,1 HCM has been known by a 
confusing array of names, reflecting its clinical heterogeneity and the skewed 
experience of early investigators.  
Hypertrophic cardiomyopathy7 is the preferred name because it describes the 
overall disease spectrum without introducing misleading inferences that left 
ventricular (LV) outflow tract obstruction is an invariable feature (hypertrophic 
obstructive cardiomyopathy [HOCM] or idiopathic hypertrophic sub aortic stenosis 
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[IHSS]). Indeed, HCM is predominantly a non obstructive disease; 75% of patients do 
not have a sizable resting outflow tract gradient.3-4  
Clinical diagnosis 
of HCM is established 
most easily and reliably 
with 2-dimensional 
echocardiography8  by 
imaging the 
hypertrophied but non 
dilated LV chamber, in 
the absence of another 
cardiac or systemic disease (e.g., hypertension or aortic stenosis) capable of producing 
the magnitude of hypertrophy evident.7 Hypertrophic cardiomyopathy may be initially 
suspected because of a heart murmur (occasionally during preparticipation sports 
examinations), positive family history, new symptoms, or abnormal ECG pattern.2  
Across the broad disease spectrum of HCM, the physical examination may not 
be a reliable method for clinical identification, given that most patients do not have LV 
outflow tract obstruction and most of the well-documented physical findings (e.g., 
loud systolic heart murmur and bifid arterial pulse) are limited to patients with outflow 
gradients.  
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PATHOPHYSIOLOGY OF HYPERTROPHIC CARDIOMYOPATHY 
 Although the pathology of HCM was first described by French pathologists in 
mid 19th century, it remained for virtually simultaneous reports of Brock and Teare in 
England 43 yrs ago to bring modern attention to this fascinating entity. Pathogenesis 
proposed was that In a normal person when Cardiac contraction occurs when calcium 
binds the troponin complex (subunits C, I, and T) and tropomyosin, making possible 
the myosin-actin interaction. Actin stimulates ATPase activity in the globular myosin 
head and results in the production of force along actin filaments. Cardiac myosin-
binding protein C, arrayed transversely along the sarcomere, binds myosin and, when 
phosphorylated, modulates contraction. In hypertrophic cardiomyopathy, mutations 
may impair these and other protein interactions, result in ineffectual contraction of the 
sarcomere, and produce hypertrophy and disarray of myocytes. Percentages represent 
the estimated frequency with which a mutation on the corresponding gene causes 
hypertrophic cardiomyopathy  
PHYSICAL EXAMINATION: 
 Left ventricular involvement is reflected by a variably displaced and forceful 
left ventricular impulse and a left sided fourth heart sound that is often palpable, 
reflecting impaired left ventricular relaxation. Patients with non-obstructive HCM 
either have no murmur or a faint grade 1/6 systolic murmur at the cardiac apex, that 
does not increase significantly with provocation. In patients with latent subaortic 
obstruction, the murmur at the apex is usually grade 1/6 to grade 2/6 in intensity, and 
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increases to grade 3/6 with appropriate provocation such as amyl nitrite inhalation, 
assuming the upright posture from the squatting position or during the Valsalva 
manoeuvre.  
Right ventricular involvement in HCM may be detected by prominent A wave 
in JVP, that rises on inspiration. A systolic ejection murmur along the high left sternal 
border often indicates subpulmonic or mid ventricular obstruction In patients with sub 
aortic obstructive HCM at rest, the murmur at or just medial to the apex is grade 3/6 to 
4/6 in intensity, and begins after the first heart sound. It is harsh and crescendo/ 
decrescendo in character with radiation to the base of the heart, reflecting the 
obstruction, and to the axilla, reflecting the concomitant mitral regurgitation.  
In 20% of patients with subaortic obstructive HCM there may be independent 
abnormalities of the mitral valve (other than systolic anterior motion) that cause mitral 
regurgitation such as abnormal papillary muscle insertions, mitral valve prolapse or 
excessive fibrotic thickening of the 
anterior mitral leaflet, resulting 
from repeated mitral leaflet–septal 
contact. In such cases there may 
also be a pansystolic murmur at 
the apex.On palpation there is 
often a bifid (spike and dome) 
arterial pulse, which at times has been referred to as a bisferiens pulse. A bisferiens 
pulse is seen in dominant aortic regurgitation. On palpation at the left ventricular apex, 
 Early systole             mitral leaflet-septal contact 
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there is often a 
double systolic 
impulse, the first 
impulse coming 
before the onset of 
the obstruction, the 
second after. 
Frequently, there is 
a triple apex beat, 
resulting from a 
palpable left atrial 
gallop sound, plus a double systolic impulse. On auscultation in subaortic obstructive 
HCM, there may be a reversed or paradoxically split second heart sound when the 
obstruction is severe or in the presence of left bundle branch block. When the mitral 
regurgitation is significant, it is often accompanied by a mitral diastolic inflow 
murmur. Rarely a mitral leaflet–septal contact sound may also be heard.  
Patients with midventricular obstruction also have an apical systolic murmur, 
although it is usually softer, grade 2/6 to 3/6, than with subaortic obstruction. A bifid 
arterial pulse, double systolic apex beat or triple apex beat are not characteristic of 
midventricular obstruction and a mitral leaflet–septal contact sound is never found. If 
the obstruction is severe, there may be reversed splitting of the second heart sound. 
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In midventricular obstruction, there is at times a very distinctive long mitral 
diastolic murmur, caused by the midventricular narrowing and asynchronous 
relaxation.  In midventricular obstruction, the size of the obstructed apical cavity 
varies considerably. It may be quite large and haemodynamically significant or very 
small and more a manifestation of cavity obliteration with a small nonobliterated 
pocket of blood remaining at the apex. The syndrome of midventricular obstruction 
with apical infarction and aneurysm formation most often results from apical 
infarction in a patient with apical HCM in whom the non infarcted hypertrophy at the 
midventricular level results in midventricular obstruction. 
ELECTROCARDIOGRAPHY 
The 12-lead ECG pattern is abnormal in 75% to 95% of HCM patients and 
typically demonstrates a wide variety of patterns.12 Q waves >0.04 second in duration 
and/or >1/3 of the ensuing R wave in depth and present in at least two leads, or left 
ventricular hypertrophy 24 or repolarization alterations with marked T-wave inversion 
in at least two leads, bundle-branch block or hemiblock with or without ST-segment 
displacement, Arrhythmias of all type particularly AF. Normal ECGs are most 
commonly encountered in family members identified as part of pedigree screening or 
when associated with mild localized LVH12 .Only a modest relation between ECG 
voltages and the magnitude of LVH assessed by echocardiography is evident. 
Nevertheless, ECGs have diagnostic value in raising a suspicion of HCM in family 
members without LVH on echocardiogram and in targeting athletes for diagnostic 
echocardiography as part of preparticipation screening.  
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ECHOCARDIOGRAPHY 
In clinically diagnosed patients, increased LV wall thicknesses range widely 
from mild (13-15 mm)3, to massive ( 30 mm [normal, 12 mm]),10, including the most 
substantial in any cardiac disease, namely, up to 60 mm 40 In trained athletes, modest 
segmental wall thickening (i.e., 13-15 mm) raises the differential diagnosis between 
extreme physiologic LVH (i.e., athlete's heart) and mild morphologic expressions of 
HCM, which can usually be resolved with noninvasive testing. Magnetic resonance 
imaging may be of diagnostic value when echocardiographic studies are technically 
inadequate or in identifying segmental LVH undetectable by echocardiography. 
Based on Echo HCM can be classified as Left ventricular, Right ventricular. In 
the left ventricular type it may be asymmetrical or concentric. The approximate 
incidence of types of HCM46 
Types of HCM Incidence % 
Left ventricular involvement 
  Asymmetrical Hypertrophy 
        Septal 
        Apical 
       Midventricular 
       Rare types 
 Symmetrical(conc.) Hypertrophy 
 
95 
80 
9 
4 
2 
5 
Right ventricular involvement - 
*Toronto General Hospital46 
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GENETICS  
Hypertrophic Right ventricular involvement in HCM may be detected by 
prominent A wave in JVP, that rises on inspiration. A systolic ejection murmur along 
the high left sternal border often indicates subpulmonic or mid ventricular obstruction 
cardiomyopathy is inherited as a mendelian autosomal dominant trait and caused by 
mutations in any 1 of 10 genes, each encoding proteins of the cardiac sarcomere 
(components of thick or thin filaments with contractile, structural, or regulatory 
functions).13(Figure 4) The physical similarity of these proteins makes it possible to 
regard the diverse HCM spectrum as a single disease entity and primary sarcomere 
disorder. The mechanisms by which disease-causing mutations cause LV hypertrophy 
(LVH) and the HCM 
disease state are 
unresolved, although 
several hypotheses 
have been 
suggested.14             
Three of the 
HCM-causing 
mutant genes predominate, namely, -myosin heavy chain (the first identified), cardiac 
troponin T, and myosin-binding protein C. The other genes each account for a minority 
of HCM cases, namely, cardiac troponin I, regulatory and essential myosin light 
chains, titin, -tropomyosin, -actin, and -myosin heavy chain. This diversity is 
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compounded by intragenic heterogeneity, with more than 150 mutations identified, 
most of which are missense with a single amino acid residue substituted with 
another.13 Molecular defects responsible for HCM are usually different in unrelated 
individuals, and many other genes and mutations, each accounting for a small 
proportion of familial HCM, remain to be identified.  
PCR was the technique used for genetic analysis. THE POLYMERASE 
CHAIN REACTION The PCR, introduced in 1985, has revolutionized the way 
DNAanalyses are performed and has become a cornerstone of molecular biology and 
genetic analysis. In essence, PCR provides a rapid way of cloning (amplifying) 
specific DNAfragments in vitro (Fig. 56-7). Exquisite specificity is conferred by the 
use of PCR primers, which are designed for a given DNAsequence. The geometric 
amplification of the DNAafter multiple cycles yields remarkable sensitivity. As a 
result, PCR can be used to amplify DNA from very small samples, including single 
cells. These properties also allow DNAamplification from a variety of tissue sources 
including blood samples, biopsies, surgical or autopsy specimens, or cells from hair or 
saliva. PCR can also be used to study mRNA. In this case, the enzyme RT is first used 
to convert the RNAto DNA, which can then be amplified by PCR. This procedure, 
commonly known as RT-PCR, is useful as a quantitative measure of gene expression. 
PCR provides a key component of molecular diagnostics. It provides a strategy for the 
rapid amplification of DNA(or mRNA) to search for mutations by a wide array of 
techniques, including DNA sequencing. PCR is also used for the amplification of 
highly polymorphic di- or trinucleotide repeat sequences, which allow various 
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polymorphic alleles to be traced in genetic linkage or association studies. PCR is 
increasingly used to diagnose various microbial pathogens. 
Contemporary molecular genetic studies throughout the past decade have 
provided important insights into the considerable clinical heterogeneity of HCM, 
including the preclinical diagnosis of affected individuals without phenotypic evidence 
of disease (ie, LVH by echocardiography or electrocardiography [ECG]).12 Although 
DNA analysis for mutant genes is the definitive method for establishing the 
diagnosis of HCM, it is not yet a routine clinical strategy.13 Because of complex, 
time-consuming, and expensive techniques, genotyping is confined to research-
oriented investigations of highly selected pedigrees. Development of rapid automated 
screening for genetic abnormalities will permit more widespread access to the power 
of molecular biology for resolving diagnostic ambiguities.  
Recently, missense mutations in the gene that encodes the -2 regulatory 
subunit of the adenosine monophosphate–activated protein kinase (PRKAG2) have 
been reported to cause familial Wolff-Parkinson-White syndrome associated with 
conduction abnormalities and LVH15 (because of glycogen accumulation in 
myocytes).15 This syndrome is most appropriately regarded as a metabolic storage 
disease distinct from HCM, which is caused by mutations in genes encoding 
sarcomeric proteins. Therefore, management and risk assessment of patients with 
Wolff-Parkinson-White syndrome and cardiac hypertrophy should not be predicated 
on data derived from patients with HCM.  
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Of potential importance for understanding HCM pathophysiology are genetic 
animal models (ie, transgenic mice and rabbits)15 and spontaneously occurring animal 
diseases.15 In particular, domestic cats with heart failure commonly show a disease 
with clinical and morphologic features remarkably similar to HCM in humans.15 
it has become clear more recently that the link between genotype and risk is not 
simple. First, Ackerman and colleagues examined the prevalence of several mutations 
in a population of 293 HCM patients at a tertiary referral centre (Mayo Clinic). 
Mutations previously reported to be "malignant" (MYH7 and TNNT2) were found in 
only three (1%) of the 293 patients. Second, there may be wide phenotypic variation 
(including natural history) between affected individuals within the same family, let 
alone between different families sharing the same genotype. For example, in a large 
Scottish family with HCM caused by a TNNT2 mutation, eight affected members died 
suddenly age < 30 years, whereas eight other affected members survived into old 
age.25 Explanations proposed to explain this phenotypic variability include: compound 
heterozygosity, modifier genes, epigenetic factors (DNA methylation and imprinting), 
epistasis (interaction between genes), post-transcriptional and post-translational 
modifications of gene products, presence of coexisting diseases, and environmental 
influences.  
DIAGNOSIS 
Novel diagnostic criteria for HCM have recently emerged and are based on 
genotype-phenotype studies showing incomplete disease expression with absence of 
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LVH in adult individuals, most commonly due to cardiac myosin-binding protein C or 
troponin T mutations.13 In both cross-sectional and serial echocardiographic studies, 
mutations in the myosin-binding protein C gene may demonstrate age-related 
penetrance of the HCM phenotype in which delayed de novo onset of LVH may occur 
in midlife and later.13 Such adult morphologic conversions dictate that it is no longer 
possible to use a normal echocardiogram to offer definitive reassurance at maturity (or 
even in middle age) that asymptomatic family members are free of a disease-causing 
mutant HCM gene13 .This observation probably necessitates a strategy of 
postadolescent echocardiographic examinations every 5 years.  
Paradoxically, a small distinctive subset of HCM patients (i.e., about 5%-10%) 
evolve into the end stage (or "burned-out" phase) characterized by LV wall thinning, 
cavity enlargement, and systolic dysfunction often resembling dilated cardiomyopathy 
and producing relentlessly progressive and irreversible heart failure.3 It is also possible 
that other adults experience subtle regression in wall thickness with aging (not linked 
with clinical deterioration), reflecting gradual, widespread remodeling. Therefore, the 
HCM phenotype is not a static disease manifestation; LVH can appear at virtually any 
age and increase or decrease dynamically throughout life.  
HCM  PHENOTYPE AND MORPHOLOGIC FEATURES  
Left Ventricular Hypertrophy. Structural heterogeneity in HCM  is  considerable, 
with no single pattern of LVH regarded as typical (Figure 5) .3 Although many patients 
show diffusely distributed LVH, almost one third have mild wall thickening localized 
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to a single segment, including the apical form16 that appears most commonly in 
Japanese people. Left ventricular hypertrophy is characteristically asymmetric, with 
the anterior septum usually predominant (Figure 5A-D, Figure 5F), although a few 
patients show a symmetric (concentric) pattern (Figure 1E).        
    
Distribution of LV wall thickening shows no direct linkage to outcome, 
although distal hypertrophy is associated with the absence of obstruction. Young 
children may present with LVH resembling HCM as part of other disease states (e.g., 
Noonan syndrome, mitochondrial myopathies, and metabolic disorders) unrelated to 
HCM-causing sarcomere protein mutations. Other markers of HCM that are not 
obligatory prerequisites for diagnosis include a hypercontractile LV and dynamic 
subaortic obstruction typically produced by mitral valve systolic anterior motion and 
 
Echo showing Hypertrophic 
cardiomyopathy 
Figure (A-D, F): Asymmetric septal  
   Hypertrophy 
Figure (E)   : Concentric 
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septal contact17 (caused by drag effect18 or possibly the Venturi phenomenon17), which 
is responsible for a loud systolic murmur.  
 The sudden deceleration of longitudinal septal motion might be caused by an 
external force, pushing or dragging the septum towards the base. However, this cannot 
be explained by the LVOT gradient itself, which develops in parallel to the septum. 
Alternatively, it might be caused by an internal unbalance of myocardial forces within 
the septum. Normal systolic radial and longitudinal myocardial thickening occurs 
almost simultaneously. Dynamic LVOT obstruction leads to a sudden rise in LV 
pressure during mid systole. The excessive rise in LV wall stress will impede further 
myocardial thickening in the radial direction and this will also hamper longitudinal 
shortening caused by the conservation of mass principle. The only segment which is 
not affected by the abnormally increased LV cavity pressure is the basal septal 
myocardial segment which lies below (downstream to) the region of mitral septal 
contact, thus being exposed to a lower mid systolic wall stress.5 Isolated longitudinal 
shortening of this basal septal segment will drag the septum towards the base, thereby 
causing the MSSD (mid systolic septal deceleration) notch. This abnormal septal 
motion may contribute further to LVOT narrowing and the positive amplifying 
feedback loop of LVOT obstruction. 
LEFT VENTRICULAR OUTFLOW TRACT OBSTRUCTION: 
A recent large study reported that patients with a resting peak instantaneous 
outflow tract gradient > 30 mm Hg were at increased risk of total mortality (RR 2.0, 
95% CI 1.3 to 3.0), of death from heart failure or stroke (RR 4.4, 95% CI 3.3 to 5.9), 
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and of SCD (RR 2.1, 95% CI 1.1 to 3.7). There was no evidence of increasing risk 
with progressively increasing gradients above this threshold.49 The negative predictive 
accuracy for SCD was very high (95%) but the positive predictive accuracy was very 
low (7%). The impact of treatments aimed at reducing outflow tract obstruction 
(medical, surgical, and alcohol septal ablation) on the risk of SCD has not been 
formally assessed. 
Cellular Components: Cardiomyopathic substrate in HCM is defined anatomically by 
several histological features based on autopsy observations. Left ventricular 
myocardial architecture is disorganized, composed of hypertrophied cardiac muscle 
cells (myocytes) with bizarre shapes and multiple intercellular connections often 
arranged in chaotic alignment at oblique and perpendicular angles (Figure 2B).1 
Cellular disarray may be widely distributed, occupying substantial portions of LV wall 
(average, 33%), and is more extensive in young patients who die of their disease.   
   Abnormal intramural coronary arteries, characterized by thickened walls with 
increased intimal and medial collagen and narrowed lumen, may be regarded as a form 
of small vessel disease (Figure 2). Such architectural alterations of the 
microvasculature, as well as the mismatch between myocardial mass and coronary 
circulation, are likely responsible for impaired coronary vasodilator reserve19 and 
bursts of myocardial ischemia19leading to myocyte death and repair in the form of 
patchy or transmural replacement scarring (Figure 2).19 Such myocardial scarring 
supports clinical evidence that ischemia frequently occurs within the natural history of 
HCM19 and may serve as the substrate for premature heart failure–related death. It is 
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also evident that the cardiomyopathic process in HCM is not confined to areas of gross 
wall thickening and that nonhypertrophied regions also contribute to ischemia or 
impaired diastolic function.20  
Disorganized cellular architecture,1 myocardial scar-ring,19 and expanded 
interstitial (matrix) collagen probably serve as arrhythmogenic substrates predisposing 
to life-threatening electrical instability. This substrate is likely the source of primary 
ventricular tachycardia and ventricular fibrillation, which appear to be the predominant 
mechanisms of sudden death,21 either primarily or in association with triggers intrinsic 
to the disease process, namely, myocardial ischemia, systemic hypotension, 
supraventricular tachyarrhythmias, or environmental variables (eg, intense physical 
exertion).  
Penetrance and variability of phenotypic expression are undoubtedly influenced by 
factors other than disease-causing mutant genes such as modifier genes (e.g., 
angiotensin-converting enzyme genotype),22 coexistent hypertension, or lifestyle. 
Indeed, several phenotypic manifestations of HCM do not primarily involve 
sarcomeric proteins, including increased interstitial collagen, abnormal intramural 
arteries, and mitral valve malformations such as elongated leaflets or direct papillary 
muscle insertion into the mitral valve.  
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CLINICAL COURSE  
Hypertrophic cardiomyopathy is unique among cardiovascular diseases by 
virtue of its potential for clinical presentation during any phase of life (from infancy to 
>90 years of age).1-3,22 Although adverse clinical consequences have been recognized 
for many years, particularly sudden cardiac death,1,2 a more balanced perspective 
regarding prognosis has evolved recently.23 
Historically, misperceptions regarding the clinical significance of HCM have 
prevailed because of its relatively low prevalence in cardiac populations, extreme 
heterogeneity, and skewed patterns of patient referral that created important selection 
biases.23 Indeed, much of the data assembled throughout the past 40 years have been 
disproportionately generated by a few tertiary centers largely composed of patients 
preferentially referred because of their high-risk status or severe symptoms requiring 
specialized care such as surgery.23 Hence, the older literature was dominated by the 
most adverse consequences of HCM, while clinically stable, asymptomatic, and 
elderly patients were underrepresented.  
Consequently, the risks of HCM would appear to have been overestimated by 
dependence on frequently cited, ominous mortality rates of 3% to 6% annually.24. 
Recent reports throughout the last 7 years from less selected regional or community-
based HCM patient cohorts cite much lower annual mortality rates, about 1%,25 not 
dissimilar to that for the general adult US population.23 Such data provide a more 
balanced view in which HCM may be associated with important symptoms and 
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premature death but more frequently with no or relatively mild disability and normal 
life expectancy.  
Elderly HCM patients ( 75 years) have been reported to compose as much as 
25% of an HCM cohort, with only a minority having severe manifestations of heart 
failure.23 Outflow obstruction is commonly evident in patients of advanced age (ie, in 
about 40%), suggesting that subaortic gradients may be well tolerated for long periods 
without adverse consequences. Indeed, HCM in elderly patients can be a genetic 
disorder caused by dominant sarcomere protein mutations most commonly in cardiac 
myosin-binding protein C and troponin I genes.26  
 
PROFILES OF PROGNOSIS AND TREATMENT STRATEGIES  
The clinical course for individual HCM patients is most appropriately viewed 
in terms of specific subgroups rather than only from perceptions of the overall disease 
spectrum. Some patients progress along certain relatively discrete, adverse pathways: 
(1) high risk for sudden death1-3 (2) congestive symptoms of heart failure with 
exertional dyspnoea and functional disability often associated with chest pain and 
usually in the presence of preserved LV systolic function23; and (3) consequences of 
atrial fibrillation (AF),27 including embolic stroke.  
Sudden Death Risk Stratification. Sudden death is the most common mode of demise 
and the most devastating and unpredictable complication of HCM.1-3 Therefore, within 
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the broad HCM disease spectrum, for which overall annual mortality rate is about 1%, 
exist small subsets at a much higher risk (perhaps at least 5% annually).  
An important but complex objective has been the identification of such higher-risk 
individuals among the vast HCM spectrum. For example, sudden death can be the 
initial manifestation of HCM, and such patients usually have no or only mild prior 
symptoms.  
Indeed, HCM is the most common cause of cardiovascular sudden death in 
young people, including trained competitive athletes (most commonly in basketball 
and football and in black athletes).28 
Highest risk for sudden death in HCM has been associated with any of the 
following noninvasive clinical markers3,23 prior cardiac arrest or spontaneous sustained 
ventricular tachycardia; family history of premature HCM-related death, particularly if 
sudden, in close relatives, or multiple; syncope and some cases of near-syncope, 
particularly when Exertional or recurrent, or in young patients when documented as 
arrhythmia-based or clearly unrelated to neurocardiogenic mechanisms; multiple and 
repetitive or prolonged bursts of nonsustained ventricular tachycardia on serial 
ambulatory (Holter) ECG recordings; hypotensive blood pressure response to exercise, 
particularly in patients younger than 50 years; and extreme LVH with maximum wall 
thickness 30 mm, particularly in adolescents and young adults.  
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There is only a suggested association23 but no clinically relevant and 
independent linkage between sudden death and outflow obstruction,3,23 although data 
on particularly large ( 100 mm Hg) gradients are limited.23 One report suggests that 
short, tunneled (bridged) segments of left anterior descending coronary artery, 
mediated by ischemia, independently convey increased risk for cardiac arrest in 
children with HCM.29 
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Presentation of HCM in young children is exceedingly uncommon and usually 
creates a clinical dilemma because of diagnosis (often fortuitous) so early in life and 
the uncertainty regarding risk over such long periods. Studies of HCM in children 
report annual mortality rates of 2% (community-based populations) to 6% (tertiary 
referral cohorts).  
It has been proposed, based on genotype-phenotype correlations, that the 
genetic defects responsible for HCM3,23,29 could represent the primary determinant and 
stratifying marker for sudden death risk, with specific mutations conveying either 
favorable or adverse prognosis. For example, some -myosin heavy chain mutations 
(e.g., Arg403Gln and Arg719Gln) and some troponin T mutations may be associated 
with a higher frequency of premature death compared with other mutations, such as 
those of myosin-binding protein C (InsG791) or -tropomyosin (Asp175Asn).3,13,16 
However, caution is warranted before strong conclusions are drawn regarding 
prognosis based solely on the available epidemiologic genetic data. Access to the 
molecular biology of HCM does not yet represent a clinically relevant strategy that 
routinely affects disease management.  
Although attention has understandably focused on high-risk HCM patients, the 
absence of risk factors and certain clinical features can be used to develop a profile of 
HCM patients at low likelihood for sudden death caused by life-threatening rhythm 
disturbances, as well as other adverse events (e.g., at a rate of <1% annually). Such 
patients with favorable prognosis constitute an important proportion of the overall 
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HCM population and generally deserve a measure of reassurance regarding their 
disease.3  
Most  HCM patients should undergo a risk stratification assessment (probably 
with the exception of patients older than 60 years) that requires, in addition to careful 
history taking and physical examination, noninvasive testing with 2-dimensional 
echocardiography, 24- or 48-hour ambulatory Holter ECGs, and treadmill (or bicycle) 
exercise testing. Such evaluation and follow-up should be carried out by (or involve) 
qualified specialists in cardiovascular medicine.  
Two groups recently reported that extreme LVH (maximum wall thickness > 
30 mm) was associated with an increased risk of SCD during follow up.50 
The other group (McKenna and colleagues) confirmed that patients with 
maximum wall thickness > 30 mm had a higher probability of SCD or AICD discharge 
than those with maximum wall thickness < 30 mm (RR 2.07, 95% CI 1.00 to 4.25). 
Severe LVH is a risk factor for SCD but its predictive accuracy is low—
sensitivity 26%, specificity 88%, positive predictive accuracy 13%, and negative 
predictive accuracy 95%.51. 
McKenna and colleagues have shown convincingly that consideration of the 
overall burden of risk factors considerably improves the predictive accuracy. They 
considered four variables (ABPR, maximum wall thickness > 30 mm, NSVT, and the 
"combined variable" of family history of SCD in at least one relative < 45 years and 
history of syncope) in a group of 368 consecutive patients. The estimated six year 
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SCD-free survival rates 
according to the number 
of risk factors present 
were as follows: 0 (n = 
203), 95% (CI 91% to 
99%); 1 (n = 122), 93% 
(CI 87% to 99%); 2 (n = 
36), 82% (CI 67% to 
96%); 3 (n = 7), 36% (CI 
0% to 75%). 
Important differential 
diagnosis of LVH is 
athletic heart. Flow chart 
above differentiates the 
clinical features. 
 
 
Prevention: In HCM, treatment strategies to reduce risk for sudden death have been 
historically predicated on drugs such as -blockers, verapamil, and antiarrhythmic 
agents (ie, quinidine, procainamide, and amiodarone). Nevertheless, there is little 
evidence30 that prophylactic pharmacological strategies and rhythm-modulating drugs 
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effectively reduce risk for sudden death; furthermore, because of its potential toxicity, 
amiodarone is unlikely to be tolerated throughout the long risk periods characteristic of 
young HCM patients.  
At present, the implantable cardioverter-defibrillator (ICD) appears to be the 
most effective treatment modality for the high-risk HCM patient, with the potential to 
alter natural history22 .In a large multicenter study, ICDs aborted potentially lethal 
ventricular tachyarrhythmias and restored sinus rhythm in almost 25% of patients 
throughout a brief 3-year follow-up. Appropriate device interventions occurred at 11% 
annually for secondary prevention (implant following cardiac arrest) and 5% annually 
for primary prevention (implant based on risk factors), usually in patients with no or 
only mild prior symptoms. Patients receiving appropriate shocks were young (mean, 
40 years), and ICDs often remained dormant for prolonged periods before discharging 
(up to 9 years), emphasizing the unpredictability of sudden death events in HCM.  
Sudden death prevention with the ICD is most strongly warranted for patients 
with prior cardiac arrest or sustained spontaneous ventricular tachycardia. Although 
multiple risk factors convey increasingly greater sudden-death risk,31 a single major 
risk factor in an individual patient may be sufficient to justify strong consideration for 
primary prevention with an ICD.. Also, physician and patient attitudes toward ICDs 
(and also access to the devices) can vary considerably among countries and cultures 
and profoundly affect clinical decision making.  
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Intense physical exertion constitutes a sudden-death trigger in susceptible 
individuals.28 Therefore, to reduce risk, disqualification of athletes with unequivocal 
evidence of HCM from most competitive sports has been prudently recommended by a 
national consensus panel.32 
Atrial Fibrillation: Atrial fibrillation is the most common sustained arrhythmia in 
HCM, accounting for unexpected hospital admissions and unscheduled work loss, and 
therefore usually justifies aggressive therapeutic strategies. Paroxysmal episodes or 
chronic AF ultimately occur in 20% to 25% of HCM patients, increase in incidence 
with age, and are linked to left atrial enlargement.23 Atrial fibrillation is reasonably 
tolerated by about one third of patients and is not an independent determinant of 
sudden death.33  
However, AF is associated with embolic stroke (incidence, about 1% annually; 
prevalence, 6%), leading to death and disability most frequently in the elderly,33as well 
as progressive heart failure, particularly when AF onset occurs before 50 years of age 
and is associated with basal outflow obstruction.33  
Paroxysmal AF may be responsible for acute clinical decompensation, 
requiring electrical or pharmacological cardioversion.34 Although data in HCM 
patients are limited, amiodarone is regarded as effective for reducing AF recurrences. 
In chronic AF, -blockers and verapamil effectively control heart rate, although A-V 
node ablation with permanent ventricular pacing may occasionally be necessary. 
Because of the potential for clot formation and embolization, anticoagulant therapy 
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with warfarin is indicated in patients with either recurrent or chronic AF. Since 1 or 2 
paroxysms of AF have been associated with the risk for systemic thromboembolism in 
HCM, the threshold for initiation of anticoagulant therapy should be low.33 However, 
such clinical decisions should be tailored to the individual patient after the obligatory 
lifestyle modifications, risk of hemorrhagic complications, and expectations for 
compliance have been considered.  
Heart Failure: Presentation. Symptoms such as exertional dyspnoea, orthopnea, 
paroxysmal nocturnal dyspnoea, and fatigue are common, characteristically in the 
presence of normal or supranormal LV contractility and independent of whether 
outflow obstruction is present .Such symptoms of HCM-related heart failure are 
usually deferred until adulthood but may occur at any age.  
Marked symptom progression (to New York Heart Association classes III and 
IV) is relatively infrequent, developing in about 15% to 20% of an unselected 
population, and such exertional disability may evolve at varying rates; deterioration is 
often gradual and punctuated with long periods of stability and day-to-day variability3            
Congestive symptoms and exertional limitation in HCM appear to be largely 
the consequence of diastolic dysfunction in which impaired LV relaxation, increased 
chamber stiffness, and compromised left atrial systolic function impede filling, leading 
to elevated left atrial and LV end-diastolic pressures with reduced stroke volume and 
cardiac output. These mechanisms result in pulmonary congestion with diminished 
exercise performance35 evidenced by reduced peak oxygen consumption. However, 
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heart failure related to diastolic dysfunction may also be intertwined with other 
pathophysiological mechanisms such as myocardial ischemia, outflow obstruction, and 
AF.3,33 
Chest pain suggestive of myocardial ischemia (with angiographically normal 
coronary arteries), either typical or atypical of angina, is a symptom commonly 
associated with exertional dyspnea.3 Myocardial perfusion defects, net lactate release 
during atrial pacing, and blunted coronary flow reserve constitute evidence of ischemia 
likely caused at least in part by an abnormal microvasculature.19 The role of ischemia 
in risk stratification is unresolved, in part because the clinical assessment of ischemia 
(and that of diastolic dysfunction) have been limited by an inability to noninvasively 
measure these abnormalities with quantitative precision.  
Drug Treatment Strategies: If exertional symptoms of heart failure intervene, it is 
conventional to initiate pharmacological therapy with negative inotropic drugs such as 
-adrenergic blockers or verapamil, independent of whether outflow obstruction is 
present3,34 .Patients who do not experience improvement of symptoms with one drug 
may subsequently benefit from the other, but combined administration is not 
advantageous.34 However, verapamil may be deleterious to some patients with severe 
outflow gradients and heart failure,17 and some investigators favor disopyramide (often 
with a -blocker) for such severely symptomatic patients with obstruction and 
verapamil or -blockers in patients who do not develop obstruction. There are 
comparatively few data available regarding the use of other calcium channel blockers 
such as diltiazem in HCM for relief of symptoms. Patients who develop severe 
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symptoms of heart failure associated with systolic dysfunction and deteriorate into the 
end stage require alternative drug treatment with diuretics, vasodilators, and 
digitalis.3,34  
-Blockers may mitigate predominantly provocable gradients (induced with 
interventions such as physiologic exercise or Valsalva maneuver, isoproterenol 
infusion, or amyl nitrite inhalation),2 and disopyramide may reduce some subaortic 
gradients at rest,36 mediated by ventricular afterload reduction and slowing of the LV 
ejection acceleration.36 For patients with outflow obstruction, risk for bacterial 
endocarditis (usually involving the mitral valve) dictates prophylactic administration 
of antimicrobial drugs, primarily to patients with obstruction, before dental procedures 
or surgery. 
 Surgical Treatment. Should severe heart failure–related symptoms become 
unrelenting and refractory to pharmacological treatment, and lifestyle unacceptable, 
subsequent therapeutic decisions are determined largely by whether basal obstruction 
to LV outflow is present (peak instantaneous gradient 50 mm Hg3 Throughout the 
past 40 years, the experience of many centers worldwide has caused the ventricular 
septal myotomy-myectomy operation (Morrow procedure) to become established as 
the standard therapeutic option (i.e., "gold standard") for adults and children with 
obstructive HCM and severe drug-refractory symptoms.3,17 However, operative 
candidates represent only a small (5%) although important subset of the overall HCM  
population.  
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Operation requires resection of a small amount of muscle (about 5 g) from the 
proximal septum extending just beyond the distal margins of mitral leaflets, thereby 
abolishing any significant impedance to LV outflow.37 Other surgeons have used a 
low-profile mitral valve prosthesis in patients judged to have unfavorable septal 
morphology or with intrinsic mitral valve disease (such as myxomatous degeneration) 
accounting for severe mitral regurgitation.  
Myotomy-myectomy performed at experienced surgical centers in the absence 
of associated conditions has acceptably low operative mortality ( 2%). Most patients 
(about 70%) achieve subjective improvement in symptoms and exercise capacity 5 
years or longer after their operation and often for extended periods. Consistent relief of 
severe symptoms following surgery is evidence that marked outflow gradients and 
increased LV systolic pressure are of clinical significance to many patients. However, 
outflow obstruction is not deleterious to all patients, since it is now evident that large 
gradients may be tolerated for long periods with no or little disability.23 Consequently, 
although the outflow gradient is a highly visible and quantifiable component of HCM, 
it is also typically labile and hemodynamically sensitive to alterations in ventricular 
volume and systemic vascular resistance,2 even after standing or a heavy meal, and 
should not be regarded as equivalent to the disease itself. Although major interventions 
can be advantageous by reducing the outflow gradient when it is judged to be 
persistent and the cause of severe symptoms, the presence per se of subaortic 
obstruction unassociated with marked disability is rarely the sole justification for such 
treatment.  
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Alternatives to Surgery. Some operative candidates may not have ready access to 
major centers experienced with myotomy-myectomy because of geographical factors, 
or they may not be regarded as favorable operative candidates because of concomitant 
medical conditions, advanced age, prior cardiac surgery, or insufficient motivation.  
Chronic dual-chamber pacing was associated with amelioration of symptoms 
and reduction of outflow gradient in many HCM patients.38 However, several 
randomized crossover clinical trials reported that subjective symptomatic benefit 
during pacing frequently occurs with little objective evidence of improved exercise 
capacity and can be largely explained as a placebo effect.38 While myotomy-myectomy 
provides superior results to pacing in most patients, a dual-chamber pacing trial prior 
to myotomy-myectomy could be of value in selected candidates, given that pacing (1) 
is implicitly less invasive than surgery or alcohol septal ablation, (2) is a more widely 
accessible method to the practicing cardiologist, (3) can permit more aggressive drug 
treatment by obviating concern for drug-induced bradycardia, (4) may be withdrawn, 
and (5) does not obviate subsequent implementation of invasive procedures. Pacing 
does not reduce sudden-death risk significantly38 or trigger LV remodeling.  
A second alternative therapy -alcohol septal ablation technique, which is a 
percutaneous coronary artery intervention using methods and technology available for 
atherosclerotic coronary artery disease.39 Absolute alcohol (about 1-4 mL) is 
introduced into the target septal perforator coronary artery branch to produce 
myocardial infarction, which in turn reduces basal septal thickness and motion, 
enlarges the LV outflow tract, and decreases mitral valve systolic anterior motion, 
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thereby mimicking the hemodynamic consequences of myotomy-myectomy.39 Indeed, 
reductions in outflow gradient associated with alcohol septal ablation have been 
reported to be similar to those resulting from myotomy-myectomy. Also, similar 
proportions of ablation and surgical patients have been reported to show subjective39 
and objective improvements in congestive symptoms and quality of life over relatively 
short periods, largely in observational studies; in addition, there are unconfirmed 
claims of diffuse regression of LVH following ablation. However, alcohol septal 
ablation in HCM  has not yet been subjected to the scrutiny of randomized or 
controlled studies.38 
Septal ablation is associated with operative morbidity and mortality, similar to 
that of myotomy-myectomy; complications include permanent pacemaker for high-
grade A-V block, coronary dissection, and large anterior infarction.39 In contrast to 
that for surgery, the postprocedural follow-up for alcohol septal ablation is relatively 
brief (about 3-5 years compared with 40 years for myotomy-myectomy).  
Heart Transplantation. Therapeutic options are considerably limited for patients who 
have the nonobstructive form of HCM and experience drug-refractory severe 
symptoms, including those in the end-stage phase. This subset of patients, among the 
broad HCM spectrum, may become candidates for heart transplantation.40  
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AIM AND OBJECTIVE 
The aim and objective of our study was to know the Prevalence of 
hypertrophic cardiomyopathy among the patients of Government Rajaji Hospital 
within the study period and to compare with the world’s prevalence rate. 
Symptom and Clinical manifestations of hypertrophic cardiomyopathy cases 
were to be reviewed based on their age of presentation and sex. To review the various 
presentation of electrocardiograph related to rate, rhythm, axis, Left atrial 
hypertrophy, Left ventricular Hypertrophy.  
Echocardiographic features of each case to be analyzed based on the left 
ventricular hypertrophy, outflow tract obstruction, types of hypertrophic 
cardiomyopathy.  
The aim was also to risk stratify based on the symptoms, past history and 
clinical findings.  With the help of Kamaraj University, HCM cases to be genetically 
analyzed for mutations in common genes related to HCM.  
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MATERIALS AND METHOD 
SETTING                         : Department of Medicine, Government Rajaji 
      Hospital, Madurai 
COLLABORATING DEPARTMENT: Department of Cardiology, Government  
     Rajaji    Hospital, Madurai 
ETHICAL APPROVAL        : The present project was approved by the 
ethical    Committee 
DESIGN OF STUDY                            : Analytical study 
PERIOD OF STUDY                            :  November 2006 to October 2007 
INCLUSION CRITERIA             : HCM cases  was taken up  based on 
echocardiographic documentation of a hypertrophied nondilated left ventricle (LV) in 
the absence of another cardiac or systemic disease that could produce the magnitude of 
hypertrophy evident at some time during the natural course of the disease as proposed 
by Dr. Maron B.J3. 
EXCLUSION CRITERIA           : Left ventricular Hypertrophy due to other causes 
          Age less than twelve years 
CONSENT          : Informed consent was obtained from all those who    
                                                         participated in the study.                                           
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METHODS:  
Selected socio-demographic, clinical and laboratory data were collected from 
the patients and recorded in a proforma. 
Socio demographic data comprised of: 
- age 
- sex 
- locality 
- occupation 
Clinical data comprised of: 
    Dyspnoea: Based on Newyork Heart Association Classification  
 Class I:  HCM with no limitation of physical activity 
     No symptoms with ordinary exertion 
Class II:  HCM with slight limitation of physical activity 
     Ordinary activity causes symptoms 
Class III: HCM with moderate limitation of physical activity 
    Less than ordinary activity causes symptoms 
          Class IV: Inability to carry out any physical activity without discomfort 
Orthopnea 
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Paroxysmal Nocturnal Dyspnea 
Exertional Chest pain 
Palpitation 
Syncope/Presyncope 
 Hypertension 
 Myocardial Infarction 
 Sudden Death in the Family members 
Systemic examination: 
 Blood Pressure taken in Forearm in Sitting Posture 
 Pulse Rate: Rate, Rhythm, volume, Special Characters 
 Cardiac Murmurs 
 Other system involvement 
 
Laboratory data included: 
- Hb% 
- Blood Sugar 
- Blood Urea 
- Serum Creatinine    
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            ECG: Rate, rhythm, axis, QT interval, ST changes, T wave changes, Chamber     
Hypertrophy, arrhythmias, Major and Minor criteria for HCM as proposed by Charan 
et al53 
            Echocardiography 
Imaging was done in the left lateral decubitus position using an    
ALOKA SSD 4000 with a multifrequency transducer equipped with Doppler tissue 
imaging software. Standard views for M mode and cross sectional studies were 
obtained. Standard techniques 
were employed for sizing the 
left ventricle and left atrium. 
The magnitude and distribution 
of left ventricular hypertrophy 
were assessed in the 
parasternal short axis plane by 
dividing the ventricle into four 
regions: anterior septum, posterior septum, lateral wall, and posterior wall. Wall 
thickness was measured at the levels of the mitral valve and the papillary muscles in 
each of the four segments. Maximum left ventricular wall thickness was defined as the 
greatest thickness in any single segment. A semi quantitative point score of left 
ventricular hypertrophy (Wigle score) was calculated using a previously described 
method. To measure the Left ventricular mass the formula was    LV mass = 1.04 
*(IVST +PWT+LVDD)3-(LVDD)3. Ejection Fraction =(100*(LVEDD3-
LVESD3))/LVEDD3                                                                                                          
 
 
39
Peak left ventricular outflow tract flow velocity was determined using 
continuous wave Doppler, and pressure gradients were calculated using the simplified 
Bernoulli equation. Transmitral left ventricular filling velocities at the tips of the 
mitral valve leaflets were obtained from the apical four chamber view using pulsed 
wave Doppler echocardiography. The transmitral left ventricular filling signal was 
traced manually and the following variables derived: peak velocity of early (E) and 
late (A) filling, and E/A ratio. 
Genetic Analysis: Genetic Studies particularly mutations in sarcomeric gene myosin 
heavy chain were studied. 
CONFLICT OF INTEREST:  
   There was no conflict of interest. 
QUESTIONNAIRE: 
 Proforma has been included in the end of this material 
FINANCIAL SUPPORT:  Nil 
MAIN OUTCOME MEASURES:  
 Analyzing various symptomology, clinical findings, and comparing with the 
Standard references. 
LIMITATIONS      :   This study was based mainly on Echocardiography .Hence any 
false positive and false negative affects the inference of the study group.     
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STATISTICAL ANALYSIS: 
Data were entered in Microsoft Excel spread sheet and analyzed utilizing the 
software - epidemiological information package 2002 (Epi Info 2002) - developed by 
centre for disease control and prevention, Alaska for World Health Organization. 
Range, mean, standard deviation and ‘p’ values were calculated using this package.  
Significance was considered if the ‘p’ value was below 0.05. 
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RESULTS 
Total number of patients attended Cardiology Department during our study 
period(Nov 2006-Oct 2007): 16680 cases. 
Out of which twenty nine was found to have hypertrophic cardiomyopathy. 
Results obtained were 
PREVALENCE: 
 Prevalence of HCM among cases attending Cardiology Department 
was 1:575. 
AGE:      
(Table 1) Age Distribution 
Cases Age in years 
No. % 
Less than 20 - - 
20-29 10 34.5 
30-39 3 10.3 
40-49 4 13.8 
50-59 7 24.1 
60-69 4 13.8 
70 & above 1 3.5 
Total 29 100 
Mean 
S.D. 
42.2 yrs 
15.4 yrs 
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Out of 29 patients, the mean age of presentation was 42.2 years with Standard 
Deviation of 15.4. 
Lowest age of presentation was twenty years. 
Oldest age of presentation was found to be seventy years. 
Maximum number of cases in the range of 20-29 years 
GENDER: 
 Out of the 29 cases  
17   male   
12  female  
Graph 1 
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SYMPTOMS: 
On analyzing various symptomology, 
Dyspnoea found to be common presentation of cardiomyopathy present in 19(65.5 %) 
of the cases and 10 cases have no dyspnoea (Class I) 
On break up Dyspnoea based on NYHA Classification 10 (34.5%)patients was in class 
I,11(37.9%) patients  in class II,7 (24.1%)were in class III, 1(3.4%) was in class IV  
Graph 2 
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Table 4 
Cases Other Symptoms 
No. % 
Orthopnea 
Present 
Absent 
 
9 
20 
 
31 
69 
PND 
Present 
Absent 
 
2 
26 
 
7.1 
92.9 
Chest pain 
Present 
Absent 
 
12 
17 
 
 
41.4 
58.6 
Palpitation 
Present 
Absent 
 
16 
13 
 
 
55.2 
44.8 
Syncope 
Present 
Absent 
 
8 
21 
 
24.6 
71.4 
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Cases Other Symptoms 
No. % 
Hypertension 
Present 
Absent 
 
 
9 
20 
 
31 
69 
MI 
Present 
Absent 
 
2 
27 
 
6.9 
93.1 
Sudden death in family 
a) First degree 
b) Second degree 
Total 
No sudden death 
 
3 
3 
6 
23 
 
10.3 
10.3 
20.7 
79.3 
 
CHESTPAIN: 
       Twelve (41.4%) cases had chest pain, out of which two cases had no other 
symptoms. Out of female had higher percent age of chest pain compare to their male 
counter part (41.6% of the female cases)  
PALPITATION: 
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          Sixteen (55.2%) cases had palpitation, out of which two cases had no 
other symptoms 
Graph - 3 
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SYNCOPE: 
         Eight (24.6%) cases had Syncope. In one case syncope alone was the 
presenting compliant. 
 
HYPERTENSION: 
   Past history of Hypertension was present in nine cases. 
MYOCARDIAL INFARCTION: 
 
 
47
 Two cases had past history of MI. 
SUDDEN DEATH IN THE FAMILY: 
  Sudden death due to cardiac within 45 years was considered as sudden 
cardiac death(SCD). Positive history of sudden death  in the family was present in six 
of our cases. First degree relative having sudden death in three of the cases. 
PHYSICAL EXAMINATION & LABORATORY INVESTIGATION: 
Table 4 
Parameter Mean S.D. 
Systolic BP 126.7 21.3 
Diastolic BP 80.3 10.4 
Pulse 77.5 22.4 
Hb% 10.59 1.67 
Urea 28.6 7.8 
Creatinine 0.95 0.19 
Blood Sugar 112.8 44.3 
 All the cases had positive clinical finding in the form of systolic murmur 
except two cases, hence insignificant for comparison. 
Ten patients have anemia with hemoglobin of < 10gm%. 
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ELECTROCARDIOGRAPHY: 
RATE and RHYTHM: 
 Twelve cases had Bradycardia in our study group. Sinus rhythm was present in 
24 cases. 
ARRHYTHMIA: 
 One  case had atrial flutter with varying block. 
Two cases had complete heart block. 
   FLUTTER WITH VARYING BLOCK 
 
PAROXYMAL ATRIAL TACHYCARDIA WITH VARYING BLOCK 
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AXIS IN ECG: 
Dispersion of cases against axis was shown in the graph. 
Graph - 5 
 
   
 
axis
1, 0
2, -30
3, -60
4, 60
5, -15
6, -30
7, 120
8, -30
9, 60
10, 30
11, -30
12, -85
13, 014, 10
15, 30
16, -30
17, 45
18, 60
19, -30
20, -50
21, 150
22, 10
23, -60
24, 100
25, 10
26, -30
27, -100
28, -20
29, 10
0 5 10 15 2 25 35
axi
 
 
50
 
ECG showing Left Axis Deviation  (- 85). 
Mean Axis of our study cases  was 6.33.Range was between 150 to 100.With 
15 cases having left axis, three cases having Right Axis deviation. 
AXIS IN ECG
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CLASSICAL Q WAVE IN V1 TO V6 
MAJOR CRITERIA IN ECG52 
 (1) Q waves >0.04 second in duration and/or >1/3 of the ensuing R wave in 
depth and present in at least two leads, or  
(2) left ventricular hypertrophy assessed by a Romhilt-Estes score 4,46or 
  (3) repolarization alterations with marked T-wave inversion in at least two 
leads in the absence of bundle-branch block or hemiblock with or without ST-segment 
displacement under the isoelectric line.  
In 24(86.2%) cases of our study, major criteria was positive. 
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Graph - 6 
 
MINOR CRTITERIA IN ECG 
Isolated left atrial enlargement assessed by a negative P wave in 
lead V1 greater than -0.03 mV-second,47  
short PR interval <120 ms,  
microvoltage assessed by a voltage <5 mV in each limb lead,  
minor Q waves in at least two leads, or bundle-branch block or 
hemiblock.48 
In 15(51.7%) cases of our study, minor criteria were positive. 
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On combining both major and minor criteria 100% of cases were positive.   
Graph - 7 
 
 
APICAL HCM 
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LEFT ATRIAL ENLARGEMENT IN ECG 
 Left atrial dilatation was present in six of our cases. 
Graph - 8 
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LEFT VENTRICULAR CHAMBER HYPERTROPHY IN ECG 
Fifteen of our patients had LVH with one case of both ventricular hypertrophy. 
Graph- 9 
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ECHOCARDIOGRAPHY IN OUR STUDY  
TYPES OF HCM  
 About 17 patients in the study group have asymmetric septal hypertrophy constituting 
59%, Five cases had Apical HCM constituting 17%, three Biventricular 10%, 
Concentric HCM 10%, Lateral HCM of the study group 
Graph - 10 
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Biventricular 
HCM 
                 
septal wall 
thickness >13mm 
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ECHO showing 
LVOT  
Apical HCM .ECHO showing 
Measurements at Apex. 
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LEFT VENTRICULAR OUTFLOW TRACT OBSTRUCTION 
Ten cases of the study group have left ventricular outflow tract obstruction >30mmHg 
Graph - 11 
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Table 5 
BASE LINE CHARACTERSITCS OF THE STUDY CASES 
Value Parameter 
Mean S.D. 
LVID (d)(mm) 43 9 
LVID (s)(mm) 28.7 8.9 
LVEF % 66.74 11.26 
IVS (d) (mm) 19.2 7.1 
IVS (s) (mm) 21.3 7.4 
LVPW (d) (mm) 12.1 3.7 
LVPW (s) (mm) 14.2 2.9 
LVM (grams) 328.97 178.95 
MV (E) (ms-1) 0.58 0.26 
MV (A) (ms-1) 0.5 0.19 
TDI (S) (ms-1) 0.0717 0.02 
TDI (E) (ms-1) 0.0555 0.022 
TDI (A) (ms-1) 0.0703 0.021 
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REGURGITATION  LESION: 
 In our cases, eleven had mitral regurgitation of Grade I - II, four cases of 
Tricuspid regurgitation, and two cases of aortic regurgitation. 
PULMONARY HYPERTENSION: 
 Six cases of our study had pulmonary hypertension mild (2), moderate (3) and 
severe (1) 
 One cases was in moderate systolic LV dysfunction. 
 One of the cases was diagnosed to have Fredriech’s Ataxia. Other incidental 
findings were Hypothyroidism, Pericardial effusion, Ovarian mass 
GENETIC ANALYSIS: 
 Three cases of study group had deletion mutation in β-MHC genes. All the 
three cases had family history of sudden death at young age. On Echocardiographic 
screening of the Family members, two daughters of the case had early features of 
HCM but they were not fully evaluated,hence not takan up for study.  
 
 
 
 
 
 
 
63
DISCUSSIONS 
PREVALENCE: 
 Average prevalence of HCM in world population was around 1:500 in general 
population. In our study prevalence rate was about 1:575 of patients attending 
cardiology department.But these cases are not the exact representative for General 
Population. 
AGE: 
On analyzing the age of the cases, Out of twenty nine cases, all the cases were 
above 20 years.Most of the cases in the study group was between 20-29 about 10 
(34.5%) in number. Mean (SD) age was 42.2(15.4). Range was 20 - 70 years. Mean 
age in the world population was 42(15). 
SEX: 
 In the our study group 17(58.6%) were male, 12(41.4%) were female. On 
comparing with the world incidence, Hypertrophic cardiomyopathy affects men and 
women equally and occurs in many races and countries, although it appears to be 
under-diagnosed in women, minorities, and under-served populations as reported by 
Elliot et al in Heart 2006. 
SYMPTOM ANALYSIS: 
 On analyzing the symptoms dyspnoea was the most common symptoms in the 
study constituting 72.4%, most of them being NYHA class II dyspnoea. Female 
population reported late in the symptomatology. Incidence wise break up was Class I 
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– 34.5%, Class II – 37.9%, Class III – 24.1%, Class IV – 3.4%. Female cases 
constituting >50% of Class III-IV cases, signifying poor awareness among this 
population group. 
 A Study at St.George Hospital,London on evaluating  956 HCM cases 
dyspnoea was the presenting compliant in 72% with break up dyspnoea was  Class I – 
62.6%,Class II -34.5%,Class III-IV – 3.4%.(in other studies NYHA >III ranges from 
33% in Brawnwald et al,19% in  Maron et al,7% in Spirilo et al)44 
Positive History of Excertional type of chest pain present in 12(41.4%) cases. 
Two cases have only chest pain as their complaint. Average incidence in the world  
literature being 28%.44 the probable reason proposed was coronary ischemia hence 
specific instruction should be given for them to avoid severe exertion Positive History 
of Palpitation present in 16 (55.2%)cases. In Two cases ,it was the only positive 
symptoms. In one series palpitation reported was 26.3%.44 It is  one of the independent 
risk factors for Sudden Death. 
Syncope history was positive in 8 (24.6%) cases of our study. Six cases  of 
our study had more than two episodes of syncope. Syncope in HCM in world literature 
was around 16.5%.44, 
  In most of the studies quotes that Sudden Death increases in this set of 
population particularly having more than two episodes in six months .In patients 
younger than 45 years the sensitivity was rather low (35%), but the specificity was 
high (82%), with positive and negative predictive accuracies of 25% and 86%, 
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respectively.45 Patients with obstructive HCM typically complain of dyspnoea, angina, 
and presyncope and /or syncope on exertion. The severity of symptoms on upright 
exertion do not necessarily correlate with the magnitude of obstructive pressure 
gradient measured in supine position. 
Past history of Hypertension was reported in 9(31%) cases. Two cases with positive 
History of MI both inferior and anterior wall has been reported. 
 
FAMILY HISTORY OF SUDDEN DEATH: 
 Family History of Sudden Death was reported in 6(20.6%) cases. Sudden death 
in the first degree relatives was three(10.3%). It is an independent risk factor for 
sudden death. A family history of one or more SCDs was associated with an increased 
risk of SCD in  many series: sensitivity (42%), specificity (79%), positive predictive 
accuracy (28%), negative predictive accuracy (88%).45 
 On evaluating physical examination, most of the patients had Bradycardia 
(12cases),with mean (S.D) average of pulse rate being 77.5(22.4)/minute. On 
auscultation 27 cases had systolic murmur varying with exertion. Ten cases of our 
study had anemia with Hb% <10gm% which may aggravate the symptoms of chest 
pain 
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ELECTROCARDIOGRAPHY: 
 All the study cases was evaluated with ECG, most common abnormal finding 
was the presence of LVH. Presence of Q wave in two consecutive leads was yet 
another coming finding. LAE was present in six of the cases. Major criteria in the 
form of LVH, Q waves in two consecutive leads, marked T wave inversion in two 
leads  was positive in 25 cases hence ECG are of much useful tool along with Echo as 
a screening test.  Abnormal Q waves, which may mimic myocardial infarction, and 
which at times reflect septal hypertrophy, are a feature of the ECG in HCM, as are 
sharply negative T waves, particularly in precordial leads V3–V5 (giant T negativity 
syndrome) typical of apical HCM  as in our cases. Sensitivity of Major criteria was 
86%  which is comparable the earlier studies in literature  (61%)52. Sensitivity of both 
Major and Minor criteria was 100%. It is extremely important to recognize that 
syncope/Presyncope may also result from atrial and ventricular arrhythmias at rest, 
even in non- obstructive HCM. Congestive heart failure is rarely seen in HCM in sinus 
rhythm. Hence these cases need continuous Holter ECG monitoring to rule out non 
sustained VT.  
ECHOCARDIOGRAPHY: 
 In our study, we looked for the presence of septal wall thickness, LVOT 
pressure  gradient , septal anterior motion abnormality, any regurgitant lesion, mid 
ventricular obstruction, biventricular involvement, apical involvement. 
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 On analyzing, 58.6 % of the cases had asymmetric septal Hypertrophy, 17.3 
cases had apical hypertrophy which was found to be less than 10% in literatures 
except in Japan which needs further evaluation in our part the country. Three cases of 
Biventricular Hypertrophy has been reported in our study which were rarely 
mentioned in other series. Occurrence of concentric type of HCM was comparable to 
other series. 
In our study ten cases had LVOT gradient of >30 mmHg. It is of clinical 
importance to distinguish between the obstructive or nonobstructive forms of HCM, 
based on the presence or absence of a LV outflow gradient under resting and/or 
provocable conditions . There is now widespread recognition that the subaortic 
gradient (30 mm Hg or more) and associated elevations in intra-cavity LV pressure 
reflect true mechanical impedance to outflow and are of pathophysiologic and 
prognostic importance to patients with HCM. Outflow obstruction is a strong, 
independent predictor of disease progression to HCM-related death (relative risk vs. 
nonobstructed patients, 2.0), to severe symptoms of New York Heart Association 
(NYHA) class III or IV. 
In our study group 11 cases had mitral regurgitation of grade I-II. The mitral 
regurgitation that results from systolic anterior motion of the anterior mitral leaflet is 
directed posteriorly into the left atrium. If the mitral regurgitation is directed anteriorly 
or centrally, then additional abnormalities of the mitral valve such as abnormal 
papillary muscles or mitral valve prolapse should be suspected. In our study septal 
anterior motion was present in nine cases, which may be the reason for MR. Tran 
esophageal Echo was done three cases Transoesophageal echo Doppler studies are 
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particularly valuable in defining these additional mitral valve abnormalities and in 
distinguishing which type of obstruction is present in the left ventricle.  
On genetic analysis  three families  had mutation for MHC genes, and on 
screening the family we could not able to detect HCM by echo  except in one family . 
Two of her daughters had HCM. One interesting finding was that one of daughter had 
Apical while other had Septal HCM.   
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CONCLUSION 
Patients attending Cardiology Department between Nov 2006-Oct 2007 (16680 
cases) were taken up for screening from which 29 cases were selected for my study 
based on inclusion criteria (a left ventricular (LV) wall thickness >/=15 mm and a 
nondilated cavity that was not associated with another cardiac disease and was 
sufficient to produce the magnitude of hypertrophy evident) for HCM and was 
analyzed clinically and genetically. Age of the cases was between 20 to 70 years 
(mean 42.2 +/- 15.4). Out of 29 cases 59% (n=17/29) were male and 41%(n=12/29) 
were female. Dyspnoea was the common symptoms(64.4%), Dyspnoea of Class III-
IV accounts for one fourth the cases. Positive history of syncope was in one third of 
the cases(28.6%(n=8/29)) Positive family history of sudden death in 20.7%(6/29),  
Electrocardiographic abnormalities in most of the cases. Presence of  Septal 
anterior motion in 31%(n=9/27), LVOT  obstruction >30mmHg in one third of the 
cases, various types of  HCM  being Septal-58.6%, Apical-17.3%, Concentric-10.3%, 
Biventricular-10.3%. 
In conclusion, prevalence of HCM was about 1:575 similar to most of studies 
reported , stressing the evidence that HCM is a relatively common genetic disease but 
these cases were not the exact representation of the general population.  
History of Syncope and SCD in the family was similar to the general 
population in other studies. 
 LVH was the most common ECG findings in our study group.  
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Major Electrocardiographic changes were present in 90% of the cases much 
higher to other series (86.2% vs 61%). 
 The incidence of Apical and Biventricular HCM were higher compared with 
other series but it needs large multicentric trial for confirmation.  
LVOT obstruction was present in 34.4% similar to other series. 
SAM was present in one third of the cases much lower than other Literature.  
From this study we can able risk stratify the cases based on Syncope, SCD in 
the family, Severe LVH, LVOT Obstruction >30mmHg. All these Factors are 
independent risk factors for Sudden Death, which needs early intervention either by 
drugs or by surgery. 
 The entire family member > 20 years has to be screened routinely.  
Three cases of the study group had mutation in MHC gene considered to be 
malignant mutation. Further genetic analysis needed for detecting other deletion 
mutations. 
. 
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PROFORMA 
CLINICAL PROFILE IN HYPERTROPHIC CARDIOMYOPATHY 
Name :                  Age:       Sex:      IP no:               CD no:    
Address:                            Occupation: 
History  : 
 Breathlessness                   NYHA class          
 Orthopnea   
 PND   
 Chestpain                           duration 
 Palpitation                          
 Syncope 
 Hypertension          
 Diabetes         
  MI 
 Smoking        
 Alcohol         
 Sudden death in family members 
Examination          : 
        JVP                                 Carotids 
        PR           
        BP               
       Apical impulse                             Character  
 
        Heart sounds    S1    S2   S3   S4       murmur 
 
        RS               P/A            CNS          
 
Investigation: 
                          Blood Hb% 
                          Blood Urea                       
                          Serum   Creatinine     
                          Blood Sugar 
ECG     : 
Echo  : 
TTE     M Mode             LVID(d)         LVID(s)            LVEF      % 
             Thickness          IVS  d             LVPW  d           LVM 
                                                s                           s                           
              SAM     
              2 D                       
          Doppler          MV   E                  AV              LVOT 
                                            A      
                                        TV                         PV            
            Mid ventricular obstruction 
            RV   involvement 
            Pulmonary   hypertension 
            TDI                     S΄                      E΄                 A΄ 
  TEE                                           
 Genetic study:                                        
 
 
Breathlessness          1 NYHA class I 
2 NYHA class II 
3       NYHA class III 
4 NYHA class IV 
Orthopnea     1 YES 
2        NO 
PND      1  YES 
      2  NO 
Palpitation      1  YES 
  2  NO 
Chest pain                 1  YES  
2         NO 
Palpitation      1 YES 
      2 NO 
SYNCOPE     1 YES   
      2 NO 
HYPERTENSION    1 YES 
      2 NO 
MI      1 YES 
      2 NO 
MURMUR     1  YES 
      2 NO 
 
SUDDEN DEATH IN THE FAMILY  1 FIRST DEGREE RELATIVE 
      2 SECOND DEGREE RELATIVE 
      3 NO SUDDEN DEATH 
AXIS      1 LEFT AXIS 
      2 RIGHT AXIS 
      3 NORMAL AXIS 
      4  INDETERMINATE 
ST CHANGES     I YES 
      2 NO 
QT CHANGES     1 YES 
      2 NO 
T WAVE INVERSION    1 YES 
      2 NO 
LEFT ATRIAL DILATATION   1 YES 
      2 NO 
VENTRICULAR HYPERTROPHY   1        LEFT 
2     RIGHT 
3    NORMAL 
MAJOR CRITERIA    1  YES 
      2 NO 
MINOR CRITERIA    1 YES 
      2 NO 
SAM      1 YES 
      2 NO 
LVOT OBSTRUCTION      1 YES 
      2 NO 
MIDVENTRICULAR OBSTRUCTION  1 YES 
      2 NO 
RIGHT VENTRICULAR INVOLVEMENT 1 YES 
      2 NO 
PULMONARY HYPERTENSION  1 MILD 
      2 MODERATE 
      3 SEVERE 
      4 NO 
MR      1 GRADE I 
      2 GRADE II 
      3 NO 
TYPES OF HCM    1 ASYMMETRIC SEPTAL 
      2 APICAL 
      3 CONCENTRIC 
      4 LATERAL 
      5 BIVENTRICULAR 
 
 
 
 
 
 
 
 
 
ABBREVIATION & ANONYMS 
DM            Diabetes mellitus           TR     Tricuspid regurgitation 
HCM          Hypertrophic cardiomyopathy MR     Mitral regurgitation 
HT            Hypertension           MI      Myocardial Infarction 
IVS        Interventricular septum        NYHA  New York Heart Association 
LVH         Left ventricular hypertrophy      PHT    Pulmonary hypertension 
LVID (D) Left ventricular Internal Diameter (diastole) 
LVID(S)   Left ventricular Internal Diameter (systole) 
LVPW      Left ventricular posterior wall  RVH   Right ventricular hypertrophy 
LVOT      Left ventricular Outflow tract  SAM    Septal anterior motion 
LVM       Left ventricular mass        SCD     Sudden cardiac death 
LAE     Left Atrial Enlargement        SR        Sinus rhythm 
MHC       Myosin Heavy Chain        VT   Ventricular Tachycardia 
 
